A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 2, 2004, Pages 357-360

  Schlapbach, Achim ^a   Heng, Richard ^a   Di Padova, Franco ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PALLADIUM; PHOSPHOTRANSFERASE INHIBITOR; QUINAZOLINE DERIVATIVE; SULFONAMIDE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CYCLIZATION; DRUG POTENCY; DRUG SYNTHESIS; IC 50; MODEL; MOUSE; NONHUMAN; PROTEIN SECRETION; STRUCTURE ACTIVITY RELATION;

EID: 0347990520     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.11.006     Document Type: Article

References (22)

1. Adams J.L., Badger A.M., Kumar S., Lee J.C. Prog. Med. Chem. 38:2001;1 Foster M.L., Halley F., Souness J.E. Drug News Perspect. 13:2000;488 Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Immunopharmacology. 47:2000;185.
2. Adams J.L., Badger A.M., Kumar S., Lee J.C. Prog. Med. Chem. 38:2001;1 Foster M.L., Halley F., Souness J.E. Drug News Perspect. 13:2000;488 Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Immunopharmacology. 47:2000;185.
3. Adams J.L., Badger A.M., Kumar S., Lee J.C. Prog. Med. Chem. 38:2001;1 Foster M.L., Halley F., Souness J.E. Drug News Perspect. 13:2000;488 Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Immunopharmacology. 47:2000;185.
4. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Gree D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R. Nature. 372:1994;739.
5. Gallagher T.F., Seibel G.L., Kassis S., Laydon J.T., Thompson S.M., Abt J.W., Soreson M.E., Smietana J.M., Hall R.F., Garigipati R.S., Bender P.E., Erhard K.F., Krog A.J., Hofmann G.A., Sheldrake P.L., McDonnell P.C., Kumar S., Young P.R., Adams J.L. Bioorg. Med. Chem. 5:1997;49.
6. Revesz L., DiPadova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Zimmerlin A.G. Bioorg. Med. Chem. Lett. 10:2000;1261 Revesz L., DiPadova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Wolf R., Zimmerlin A.G. Bioorg. Med. Chem. Lett. 12:2002;2109.
7. Revesz L., DiPadova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Zimmerlin A.G. Bioorg. Med. Chem. Lett. 10:2000;1261 Revesz L., DiPadova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Wolf R., Zimmerlin A.G. Bioorg. Med. Chem. Lett. 12:2002;2109.
8. Bemis, G. W.; Salituro, F. G.; Duffy, J. P.; Cochran, J. E.; Harrington, E. M.; Murcko, M. A.; Wilson, K. P.; Su, M.; Galullo, V. P., WO 98/27098, 1998. Ferraccioli G.F. Curr. Opin. Anti-inflam. Immunomod. Invest. Drugs. 2:2000;74.
9. Ninomiya K., Shioiri T., Yamada S. Tetrahedron. 30:1974;2151.
10. Knoelker H.-J., Braxmeier T., Schlechtingen G. Angew. Chem., Int. Ed. 34:1995;2497.
11. (a). Recently a related series of p38 inhibitors was disclosed by the Merck group: Natarajan S.R., Wisnoski D.D., Singh S.B., Stelmach J.E., O'Neill E.A., Schwartz C.D., Thompson C.M., Fitzgerald C.E., O'Keefe S.J., Kumar S., Hop C.E.C.A., Zaller D.M., Schmatz D.M., Doherty J.B. Bioorg. Med. Chem. Lett. 13:2003;273. (b) Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., Hop C.E.C.A., Wang Z., Strauss J.R., Cameron P.M., Nichols E.A., O'Keefe S.J., O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., Doherty J.B. Bioorg. Med. Chem. Lett. 13:2003;277.
12. (a). Recently a related series of p38 inhibitors was disclosed by the Merck group: Natarajan S.R., Wisnoski D.D., Singh S.B., Stelmach J.E., O'Neill E.A., Schwartz C.D., Thompson C.M., Fitzgerald C.E., O'Keefe S.J., Kumar S., Hop C.E.C.A., Zaller D.M., Schmatz D.M., Doherty J.B. Bioorg. Med. Chem. Lett. 13:2003;273. (b) Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., Hop C.E.C.A., Wang Z., Strauss J.R., Cameron P.M., Nichols E.A., O'Keefe S.J., O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., Doherty J.B. Bioorg. Med. Chem. Lett. 13:2003;277.
13. A phosphorylated form of His-p38α MAP kinase of murine origin (10 ng/well) and immobilized GST-ATF-2 as substrate in the presence of 120 μM cold ATP was used to perform the kinase assay.
14. Human peripheral blood mononuclear cells were incubated with the inhibitor and stimulated with LPS/IFNγ for 3 h. TNFα levels in the supernatants were determined by ELISA.
15. (a) Guram A.S., Rennels R.A., Buchwald S.L. Angew. Chem., Int. Ed. 34:1995;1348
16. (b) Wolfe J.P., Rennels R.A., Buchwald S.L. Tetrahedron. 52:1996;7525
17. (c) Yang B.H., Buchwald S.L. Org. Lett. 1:1999;35.
18. 8b describe a similar CuI driven cyclization starting from protected ureas. Pd catalyzed reactions of aryl halides with ureas leading to linear derivatives have also been reported: Madar D.J., Kopecka H., Pireh D., Pease J., Pliushev M., Sciotti R.J., Wiedeman P.E., Djuric S.W. Tetrahedron Lett. 42:2001;3681 Artamkina G.A., Sergeev A.G., Beletskaya I.P. Tetrahedron Lett. 42:2001;4381 Yin J., Buchwald S.L. J. Am. Chem. Soc. 124:2002;6043.
19. 8b describe a similar CuI driven cyclization starting from protected ureas. Pd catalyzed reactions of aryl halides with ureas leading to linear derivatives have also been reported: Madar D.J., Kopecka H., Pireh D., Pease J., Pliushev M., Sciotti R.J., Wiedeman P.E., Djuric S.W. Tetrahedron Lett. 42:2001;3681 Artamkina G.A., Sergeev A.G., Beletskaya I.P. Tetrahedron Lett. 42:2001;4381 Yin J., Buchwald S.L. J. Am. Chem. Soc. 124:2002;6043.
20. Wolfe J.P., Buchwald S.L. Angew. Chem., Int. Ed. 38:1999;2413.
21. -).
22. 8-Week old female OF1 mice were dosed perorally by gavage with solutions of the compound in DMSO/cornoil. 1 h after dosing LPS (20 mg/kg) was injected iv. After another hour blood was collected and TNFα levels were determined using a mouse-specific ELISA.